Bellicum Pharmaceuticals, Inc. (BLCM) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) have been given an average rating of “Buy” by the eight analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $24.60.

BLCM has been the topic of several recent research reports. Jefferies Group restated a “buy” rating and issued a $16.00 price target on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Wednesday. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. Finally, ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd.

In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $9.33, for a total transaction of $159,701.61. Following the transaction, the chief financial officer now owns 31,585 shares in the company, valued at approximately $294,688.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alan A. Musso sold 6,206 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $9.89, for a total value of $61,377.34. The disclosure for this sale can be found here. Insiders sold a total of 23,810 shares of company stock worth $225,657 in the last 90 days. 18.77% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BLCM. Point72 Asset Management L.P. acquired a new position in Bellicum Pharmaceuticals during the 3rd quarter worth approximately $4,723,000. JPMorgan Chase & Co. increased its position in Bellicum Pharmaceuticals by 10.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock worth $28,811,000 after purchasing an additional 227,668 shares during the period. Vanguard Group Inc. increased its position in Bellicum Pharmaceuticals by 13.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock worth $14,092,000 after purchasing an additional 144,854 shares during the period. Numeric Investors LLC acquired a new position in Bellicum Pharmaceuticals during the 2nd quarter worth approximately $1,137,000. Finally, Goldman Sachs Group Inc. increased its position in Bellicum Pharmaceuticals by 223.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock worth $1,612,000 after purchasing an additional 95,336 shares during the period. Institutional investors own 55.28% of the company’s stock.

Bellicum Pharmaceuticals (BLCM) opened at $8.90 on Friday. The stock has a market capitalization of $295.72, a PE ratio of -2.98 and a beta of 1.18. Bellicum Pharmaceuticals has a 52-week low of $7.41 and a 52-week high of $15.55. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.08 and a quick ratio of 6.08.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.03 million. The business’s revenue was up 18.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.66) EPS. equities analysts expect that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.

WARNING: “Bellicum Pharmaceuticals, Inc. (BLCM) Given Consensus Recommendation of “Buy” by Brokerages” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/01/12/bellicum-pharmaceuticals-inc-blcm-given-consensus-recommendation-of-buy-by-brokerages.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply